New stem cell transplant approach aims to tame deadly bone marrow cancer

NCT ID NCT03118492

Ongoing Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a reduced-intensity stem cell transplant using a half-matched donor and a drug called cyclophosphamide after the transplant to prevent rejection. The goal is to see if this approach is safe enough for patients with advanced myelofibrosis, a serious bone marrow disorder. Only 22 patients are enrolled, and the main focus is on side effects and tolerability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: donor blood stem cells and cyclophosphamide
What this could lead to: If successful, this approach could offer a safer transplant option for patients with advanced myelofibrosis, potentially controlling the disease long-term.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not effectiveness. The transplant carries serious risks including infection, graft failure, and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SECONDARY MYELOFIBROSIS

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.